{"denoms":[{"counts":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"98"}],"units":"Participants"}],"groups":[{"description":"bortezomib, dexamethasone, and thalidomide","id":"BG000","title":"Three Drug Regimen (VDT)"},{"description":"bortezomib, dexamethasone, thalidomide, and cyclophosphamide","id":"BG001","title":"Four Drug Regimen (VDTC)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"90"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.04","value":"55.1"},{"groupId":"BG001","spread":"8.27","value":"55.8"},{"groupId":"BG002","spread":"7.65","value":"55.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"51"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"47"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}